Viropro Inc.
Built from real-time financials, refreshed daily. For a full Analyst Grade with bull/bear case, price targets, and qualitative risk analysis, generate a VPRO research report →
Price Chart
About the company
Viropro Inc. , a subsidiary of Alpha Biologics Limited, functions as a contract research and manufacturing organization (CRMO), primarily engaged in the development and production of biotherapeutic proteins aimed at treating diverse medical conditions. The company additionally facilitates the industrial-scale manufacturing of biogeneric therapeutic proteins through the licensing of its proprietary technologies, targeting illnesses like cancer, diabetes, hepatitis, and multiple sclerosis.
- CEO
- Michelle Leanne Edythe Peake
- IPO
- 1995
- HQ
- San Jose, CA, US
Get TickerSpark's AI analysis on VPRO
Create an account to generate AI analysis on any ticker — technical setup, analyst consensus, earnings watch, insider pulse, financial health, and peer context. Ready in about a minute.
Get Pro Access →Already have an account? Log in
Similar companies
Peers in the same neighborhood.
- Market Cap
- $25.40K
- P/E
- -0.00
- PEG
- 0.00
- P/S
- 0.04
- P/B
- 0.00
- EV/EBITDA
- -0.15
- Div Yield
- 0.00%
- Gross Margin
- 100.00%
- Op Margin
- -174.49%
- Net Margin
- -176.88%
- ROE
- -185.71%
- ROIC
- 0.00%
Latest fiscal year · YoY change
- Revenue
- $571.10K+0.0%
- Gross Profit
- $571.10K+0.0%
- Op Income
- $-996,515
- Net Income
- $-1,010,149+31.0%
- EPS
- $-0.01+0.0%
- OCF Growth
- +6.6%
- FCF Growth
- +6.9%
- 52W High
- $0.00
- 52W Low
- $0.00
- 50D MA
- $0.00
- 200D MA
- $0.00
- Beta
- 3.77
- RSI (14)
- 48
- Avg Volume
- 70.83K
No earnings-call transcripts are available for VPRO yet.
- Free Float
- 42.8%
- Shares Outstanding
- 1.27B
- Float Shares
- 543.73M
Our VPRO coverage
Recent articles, reports, and earnings notes.
No research on VPRO yet
For a full analyst-grade research report — grades, price targets, financials, chart analysis — generate one on demand.
Generate VPRO report →